Award
National Cancer Institute 5R44CA295197-02
Comparison of convection enhanced delivery systems in a randomized controlled clinical study of recurrent Grade 3-4 glioma patients
Recipient
CREOSALUS, INC.
Award Amount
$682,122.00
Ceiling
$682,122.00
Awarded
August 29, 2025
Identifier
5R44CA295197-02
A clinical study to evaluate the safety and efficacy of an innovative convection enhanced delivery catheter system for treating recurrent Grade 3-4 glioma patients, aiming to improve drug distribution and outcomes for glioblastoma.
Description
This project aims to increase therapeutic coverage of glioblastoma (GBM) tumors using an innovative convection enhanced delivery (CED) catheter. It proposes to evaluate the safety and efficacy of the PBIC system in treating recurrent Grade 3-4 glioma patients through a randomized controlled trial comparing the PBIC catheter with the current Duke CED end port catheter. The study involves clinical trials, innovative drug delivery systems, and advanced imaging techniques to improve treatment for brain tumors.